Search research articles
Contact Us
Filters
Showing results (81-90 of 111) with videos related to
Page
of 12
Sort By:
Therapeutic Innovation & Regulatory Science
|
May 17, 2021
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
Len Rosenberg, Hugh Levaux, Ross L Levine, et al.
Blood
|
September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Cancer Discovery
|
August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Blood
|
July 13, 2012
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
Pearlly Yan, David Frankhouser, Mark Murphy, et al.
Blood
|
February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M Devine, Kouros Owzar, William Blum, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 111) with videos related to
Sort By:
Page
of 12
Therapeutic Innovation & Regulatory Science
|
May 17, 2021
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
Len Rosenberg, Hugh Levaux, Ross L Levine, et al.
Blood
|
September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Cancer Discovery
|
August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Blood
|
July 13, 2012
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
Pearlly Yan, David Frankhouser, Mark Murphy, et al.
Blood
|
February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M Devine, Kouros Owzar, William Blum, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Page
of 12